Outlook Therapeutics, Inc.
NASDAQ:OTLK
Overview | Financials
Company Name | Outlook Therapeutics, Inc. |
Symbol | OTLK |
Currency | USD |
Price | 1.42 |
Market Cap | 33,590,952 |
Dividend Yield | 0% |
52-week-range | 0.87 - 12.85 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. C. Russell Trenary III |
Website | https://www.outlooktherapeutics.com |
An error occurred while fetching data.
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD